[go: up one dir, main page]

MX2018010196A - Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas. - Google Patents

Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.

Info

Publication number
MX2018010196A
MX2018010196A MX2018010196A MX2018010196A MX2018010196A MX 2018010196 A MX2018010196 A MX 2018010196A MX 2018010196 A MX2018010196 A MX 2018010196A MX 2018010196 A MX2018010196 A MX 2018010196A MX 2018010196 A MX2018010196 A MX 2018010196A
Authority
MX
Mexico
Prior art keywords
fusion proteins
lysosomal enzyme
enzyme fusion
targeted therapeutic
therapeutic lysosomal
Prior art date
Application number
MX2018010196A
Other languages
English (en)
Inventor
K Pinkstaff Jason
Moshashaee Saeed
Shaywitz Adam
Ciaccio Natalie
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of MX2018010196A publication Critical patent/MX2018010196A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

La presente descripción se refiere en general a las proteínas de fusión de enzimas lisosomales útiles para tratar enfermedades por depósito lisosomal, formulaciones líquidas que comprenden dichas proteínas de fusión y métodos asociados útiles para tratar las enfermedades por depósito lisosomal en mamíferos.
MX2018010196A 2016-02-24 2017-02-24 Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas. MX2018010196A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662299188P 2016-02-24 2016-02-24
US201662428221P 2016-11-30 2016-11-30
PCT/US2017/019343 WO2017147414A1 (en) 2016-02-24 2017-02-24 Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof

Publications (1)

Publication Number Publication Date
MX2018010196A true MX2018010196A (es) 2018-11-19

Family

ID=58314512

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018010196A MX2018010196A (es) 2016-02-24 2017-02-24 Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
MX2024012898A MX2024012898A (es) 2016-02-24 2018-08-23 Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024012898A MX2024012898A (es) 2016-02-24 2018-08-23 Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas

Country Status (13)

Country Link
US (3) US11345904B2 (es)
EP (2) EP3419651B1 (es)
JP (1) JP7109369B2 (es)
KR (1) KR102891965B1 (es)
CN (1) CN109069595A (es)
AU (1) AU2017222620B2 (es)
BR (1) BR112018017322A2 (es)
CL (1) CL2018002430A1 (es)
IL (1) IL261246B2 (es)
MX (2) MX2018010196A (es)
RU (1) RU2751235C2 (es)
WO (1) WO2017147414A1 (es)
ZA (1) ZA201805648B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY197218A (en) 2015-07-06 2023-06-02 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
US11345904B2 (en) 2016-02-24 2022-05-31 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof
MX2019007824A (es) * 2016-12-28 2019-09-09 Japan Chem Res Preparacion liofilizada.
NZ760232A (en) 2017-06-07 2023-05-26 Regeneron Pharma Compositions and methods for internalizing enzymes
US20200277584A1 (en) 2017-10-02 2020-09-03 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
WO2019222663A1 (en) 2018-05-17 2019-11-21 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
EP3811962A4 (en) * 2018-06-25 2022-03-16 JCR Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US20040005309A1 (en) 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
WO2002087510A2 (en) 2001-04-30 2002-11-07 Symbiontics, Inc. Subcellular targeting of therapeutic proteins
CA2463473A1 (en) 2001-10-16 2003-04-24 Symbiontics Inc. Targeted therapeutic proteins
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
CA2487815A1 (en) 2002-05-29 2003-12-11 Symbiontics, Inc. Targeted therapeutic proteins
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
CA2553955C (en) 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2633860B1 (en) * 2007-12-21 2019-05-08 Aptevo BioTherapeutics LLC Stabilized factor IX formulations containing trehalose
PT2279210T (pt) 2008-05-07 2017-07-10 Biomarin Pharm Inc Péptidos de direcionamento lisossomal e suas utilizações
ES2758827T3 (es) * 2009-06-17 2020-05-06 Biomarin Pharm Inc Formulaciones para enzimas lisosómicas
KR20120027031A (ko) * 2009-06-18 2012-03-20 와이어쓰 엘엘씨 소형 모듈 면역제약용 동결건조 제제
NZ605863A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Methods and compositions for cns delivery of iduronate-2-sulfatase
HRP20211520T1 (hr) * 2010-06-25 2021-12-24 Shire Human Genetic Therapies, Inc. Postupci i pripravci za dostavu iduronat-2-sulfataze u središnji živčani sustav
NZ605871A (en) 2010-06-25 2015-02-27 Shire Human Genetic Therapies Treatment of sanfilippo syndrome type b
KR101949293B1 (ko) * 2011-05-05 2019-02-18 웰스태트 이뮤노테라퓨틱스, 엘엘씨 보체 인자 ｂ 유사체 및 그의 용도
EP2793922B1 (en) 2011-12-23 2019-10-30 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
DK2925776T3 (en) * 2012-11-27 2018-09-03 Biomarin Pharm Inc TARGETED THERAPEUTIC LYSOSOMAL ENZYMUS FUSION PROTEINS AND APPLICATIONS THEREOF
US11345904B2 (en) 2016-02-24 2022-05-31 Biomarin Pharmaceutical Inc. Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof

Also Published As

Publication number Publication date
RU2751235C2 (ru) 2021-07-12
EP4275751A3 (en) 2023-12-27
KR20180114199A (ko) 2018-10-17
US11345904B2 (en) 2022-05-31
AU2017222620A1 (en) 2018-09-06
CL2018002430A1 (es) 2018-12-28
IL261246B (en) 2022-11-01
JP7109369B2 (ja) 2022-07-29
US20240263160A1 (en) 2024-08-08
US20200297821A1 (en) 2020-09-24
US20220251526A1 (en) 2022-08-11
EP3419651C0 (en) 2023-10-25
IL261246B2 (en) 2023-03-01
ZA201805648B (en) 2023-01-25
IL261246A (en) 2018-10-31
EP3419651B1 (en) 2023-10-25
CN109069595A (zh) 2018-12-21
RU2018132639A3 (es) 2020-07-15
EP4275751A2 (en) 2023-11-15
BR112018017322A2 (pt) 2019-01-02
AU2017222620B2 (en) 2022-06-16
KR102891965B1 (ko) 2025-11-27
MX2024012898A (es) 2024-11-08
EP3419651A1 (en) 2019-01-02
RU2018132639A (ru) 2020-03-25
WO2017147414A1 (en) 2017-08-31
JP2019506439A (ja) 2019-03-07
CA3015358A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2018010196A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
PH12020550510A1 (en) Fusion proteins comprising enzyme replacement therapy enzymes
CY1123676T1 (el) Συνθεσεις και μεθοδοι για την εσωτερικοποιηση ενζυμων
CL2020003392A1 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172)
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
PH12018500810A1 (en) Antibody agents specific for human cd19 and uses thereof
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
EP4421094A3 (en) Targeted therapeutic agents and uses thereof
PH12018502361B1 (en) Gdf15 fusion proteins and uses thereof
AU2017241807A1 (en) Medium, methods, cells and secreted factors for stem cell culture and therapy
MX2020005170A (es) Formulaciones de proteinas de fusion vegfr-fc.
MX367024B (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y usos de las mismas.
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
CA2905972C (en) Gla domains as targeting agents
MA40460A (fr) Ciblage lysosomial et utilisation correspondante
MX2017009937A (es) Cepas fungicas y metodos de uso.
EP3998341A3 (en) Adenoviral vectors
SG10201804952QA (en) Glucosylceramide synthase inhibitors
MX389168B (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
MX2018015110A (es) Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos.
MX2019006446A (es) Métodos para inducir tolerancia inmunológica a factores de coagulación.